Klin Farmakol Farm. 2010;24(4):197-206

Biological therapies in rheumatology

Hana Ciferská1, Pavel Horák1, Jan Strojil2, Martina Skácelová1
1 III. interní klinika FN a LF UP v Olomouci
2 Ústav farmakologie, LF UP v Olomouci

The goal of this short review is to inform readers about the position and utilization of biological agents in therapy of selected rheumatic

disorders. The advancement of biological agents in last two decades and their introduction in clinical practice led to prognosis improvement

in very active rheumatoid and psoriatic arthritis and ankylosing spondylitis patients, who did not respond to conventional

therapy. The authors discuss the selected biological agents – their indications, the follow up of their effects, the adverse events and

pitfalls of their usage.

Keywords: biological therapy, TNFα inhibitors, rheumatic arthritis, ankylosing spondylitis, psoriatic arthritis

Published: December 31, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ciferská H, Horák P, Strojil J, Skácelová M. Biological therapies in rheumatology. Klin Farmakol Farm. 2010;24(4):197-206.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kvamme MK, Kristiansen IS, Lie E, Kvien TK. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Rheumatology (Oxford). 2008; 47(11): 1664-1670. Go to PubMed...
    2. Hueber AJ, McInnes IB. Immune regulation in psoriasis and psoriatic arthritis-recent developments. Immunol Lett. 2007; 114(2): 59-65. Go to original source... Go to PubMed...
    3. Bacquet-Deschryver H, Jouen F, Quillard M, et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients J Clin Immunol. 2008; 28(5): 445-455. Go to original source... Go to PubMed...
    4. Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and antiTNF-alpha agents. Autoimmun Rev. 2007; 7(1): 35-41. Go to PubMed...
    5. Kukar M, Petryna O, Efthimiou P. Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. Biologics. 2009; 3: 443-457. Go to original source...
    6. Nannini C, Cantini F, Niccoli L, et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum. 2009 15; 61(6): 801-812. Go to original source... Go to PubMed...
    7. Combe B, Landewe RB, Lukas C, et al. EULAR recommendations for management of early arthritis. Ann Rheum Dis 2006; 66: 34-45. Go to original source... Go to PubMed...
    8. Šenolt L. Perspektivy biologické léčby revmatoidní artritidy - nové terapeutické cíle. Farmakoterapie 2008; 4: 645-652.
    9. Olejárová M. Biologická léčba v revmatologii. Mladá Fronta 2010 ISBN 9788020422811.
    10. Vencovský J, Tegzová D, Krofta K, Pavelka K. Doporučení České revmatologické společnosti k biologické léčbě blokádou TNF - doplněk standardních léčebných postupů u revmatoidní artritidy. Čes Revmatol 2004; 12: 14-20.
    11. Bečvář R, Vencovský J, Němec P, Suchý D, Procházková L, Pavelka K. Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. Účinnost a strategie léčby. Čes Revmatol 2007; 15: 73-90.
    12. Štolfa J. Biologická léčba psoriatické artritdiy. Remedia 2005; 15: 261-271.
    13. Pavelka K, Štolfa J, Vencovský J. Doplněk standardních léčebných postupů u ankylozující spondylitidy. Čes Revmatol 2004; 12: 20-30.
    14. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36(12): 1681-1690. Go to original source... Go to PubMed...
    15. Smolen JS, Han C, Bala M, et al. ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005; 52(4): 1020-1030. Go to original source... Go to PubMed...
    16. Smolen JS, Han C, van der Heijde DM, et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009; 68(6): 823-827. Go to original source... Go to PubMed...
    17. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52(2): 582-591. Go to original source... Go to PubMed...
    18. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008; 35(5): 869-876. Go to PubMed...
    19. van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol. 2008; 27(8): 1021-108. Go to original source... Go to PubMed...
    20. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003; 48(1): 35-45. Go to original source... Go to PubMed...
    21. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003; 30(12): 2563-2571. Go to PubMed...
    22. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54(1): 26-37. Go to original source... Go to PubMed...
    23. Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis JC Jr; ATLAS Study Group. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 2008; 35(7): 1346-1353. Go to PubMed...
    24. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009; 68(5): 702-709. Go to original source... Go to PubMed...
    25. van der Heijde D, Klareskog L, Landewé R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007; 56(12): 3928-3939. Go to original source... Go to PubMed...
    26. Voulgari PV. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Rev Clin Immunol. 2010; 6(5): 721-733. Go to original source... Go to PubMed...
    27. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009; 68(6): 789-796. Go to original source... Go to PubMed...
    28. Ramiro S, van Tubergen AM, Landewé RB. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis. Expert Rev Clin Immunol. 2010; 6(5): 713-720. Go to original source... Go to PubMed...
    29. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009; 68(6): 805-811. Go to original source... Go to PubMed...
    30. Coiffier B, Haioun C, Ketterer N, Engert A Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998 15; 92(6): 1927-1932.
    31. Emery P, Kremer JM, Moreland R, et al. Long-term efficacy and safety of abatacept through 5 years of treatment in rheumatoid arthritis patients with an inadequate response to methotrexate. Rheumatology 2008; 47(Suppl 2): 48.
    32. Looney RJ. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence. Drugs. 2006; 66(5): 625-639. Go to original source... Go to PubMed...
    33. Li T, Gignac M, Wells G, et al. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Clin Ther. 2008; 30(4): 734-748. Go to original source... Go to PubMed...
    34. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008; 67(8): 1096-10103. Go to original source... Go to PubMed...
    35. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009; 19(1): 12-19. Go to original source... Go to PubMed...
    36. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010; 69: 88-96. Go to original source... Go to PubMed...
    37. Cunnane G, Madigan A, Murphy E, et al. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology 2001; 40: 62-69. Go to original source... Go to PubMed...
    38. Pavelka K, Forejtová S, Stolfa J, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol. 2009; 27(6): 958-963. Go to PubMed...
    39. Vencovský J. a výbor České revmatologické společnosti. Bezpečnost biologické léčby - Doporučení České revmatologické společnosti. Čes Revmatol 2009; 17(3): 146-160.
    40. Breedvela F, Emery P, Neystone E, et al. Anfliximab in active early rheumatoid arthritis Ann Rheum Dis. 2004; 63(2): 149-155. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.